Chemical Biology and Drug Design
AUGUST 23, 2023
We hypothesized that ligustrazine could protect liver by decreasing the inflammation response, protein production, and apoptosis in THS rats. The protein expressions were detected via western blot. Ligustrazine at doses of 100 and 1000 μg/mL was administrated in Kupffer cells isolated from THS rats.
Drug Discovery World
APRIL 17, 2024
CAMP4 is the only company modulating gene expression at the transcriptional level to increase mRNA production and thereby increase healthy protein production. DS: You say on your website that your approach is applicable to any disease where increasing protein expression is beneficial.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Broad Institute
AUGUST 24, 2022
Louis have identified biological markers in triple negative breast cancer (TNBC) that are associated with resistance to chemotherapy treatment. It is imperative that we develop approaches to predict response so that only effective treatments are given. 33, was associated with resistance to chemotherapy treatment.
Drug Discovery World
NOVEMBER 8, 2023
Helmut Salih, MD, Professor for Translational Immunology, Medical Director, Clinical Collaboration Unit Translational Immunology, University Hospital Tuebingen and DKFZ Heidelberg, Germany; Co-Founder, TWYCE GmbH, on: ‘An optimised IgG-Based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers’. Claes Gustafsson, Ph.D,
Drug Discovery World
APRIL 30, 2024
The biggest growth driver for mRNA therapeutics came from the Covid-19 pandemic, when mRNA-based vaccines proved effective in treating SARS-CoV-2, and pharmaceutical companies such as Pfizer/BioNTech and Moderna were successful in bringing these treatments to market. The mice given the treatment survived for over three months.
Drug Discovery World
NOVEMBER 9, 2023
Sandra Ergueta-Carballo, PhD, Project Coordinator, University of Cambridge, on: ‘Advancing snake envenomation treatment: designing the next generation of antivenoms’. Lei Shi, PhD, Senior Vice President, R&D, Biointron Biological, on: ‘Accelerating early discovery through htp and high-speed antibody production’.
The Pharma Data
DECEMBER 3, 2020
New preclinical data provide additional evidence of the potential for TANGO antisense oligonucleotides (ASOs) to provide a gene-specific, disease-modifying treatment for Dravet syndrome. In this study, treatment with a TANGO ASO restored Dravet syndrome mouse PV interneuron firing frequency to that of wild-type mice. Lori Isom, Ph.D.,
Expert insights. Personalized for you.
100 
Let's personalize your content